Equities research analysts at Maxim Group began coverage on shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) in a report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $3.00 price target on the biotechnology company’s stock. Maxim Group’s target price would suggest a potential upside of 374.68% from the stock’s previous close.

The analysts wrote, “Curing hematological malignancies with a bone marrow transplant (BMT) requires patients to be in complete remission (CR), extremely difficult if not impossible in the relapsed/refractory setting. Iomab-B induces 100% CRs and ablative conditioning for BMT, and as a result drives a superior one-year survival (r/r AML acute myeloid leukemia) versus standard of care approaches (30% vs. 10% at one year, 19% vs. 0% at two years) and could become the new standard of care.””

Separately, Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $5.20.

Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 0.632 on Thursday. Actinium Pharmaceuticals has a 12-month low of $0.54 and a 12-month high of $2.15. The stock’s market cap is $50.57 million. The firm’s 50-day moving average price is $0.64 and its 200-day moving average price is $1.17.

WARNING: “Actinium Pharmaceuticals Inc (ATNM) Now Covered by Analysts at Maxim Group” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/actinium-pharmaceuticals-inc-atnm-now-covered-by-analysts-at-maxim-group.html.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Virtu KCG Holdings LLC boosted its stake in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) by 957.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 442,964 shares of the biotechnology company’s stock after acquiring an additional 401,084 shares during the period. Virtu KCG Holdings LLC owned about 0.76% of Actinium Pharmaceuticals worth $540,000 as of its most recent SEC filing.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.